INTRODUÇÃO: O presente estudo avaliou o tratamento com injeções intravítreas de Bevacizumabe (IVB) associadas à panfotocoagulação (PFC) da retina na retinopatia diabética proliferativa (RDP) de alto risco com ou sem edema macular (EM). MÉTODOS: Ensaio clínico randomizado, prospectivo, aberto e mascarado composto por pacientes com Diabetes melitos (DM) tipo 2. A acuidade visual (AV) foi medida com a tabela Early Treatment Diabetic Retinopathy Study e a sensibilidade ao contraste (SC) pela da tabela Vistech Consultants Incorporation 6500. Os pacientes foram submetidos a exame de angiofluoresceinografia para observação de neovascularização retiniana e isquemia macular e à tomografia de coerência óptica (OCT), para se obter a espessura foveal (EF) e o volume macular (VM). Após os exames, um dos olhos do mesmo paciente foi randomizado para realizar somente PFC, grupo controle (GC), e o outro para PFC associado a injeções IVB, grupo de estudo (GE). A hemorragia vítrea (HV) e a presença de complicações também foram avaliadas. RESULTADOS: Dos 42 pacientes incluídos, 35 completaram o estudo. A média de idade foi de 56±8 anos, com predominância do gênero masculino 21 (60%). Vinte e seis (74%) pacientes eram portadores de Hipertensão Arterial Sistêmica com média de duração de 9±10 anos. A média de duração do DM foi de 18±9 anos sendo 23 (66%) usuários de insulina e 21 (68,5%), fácicos. A AV e a SC não demonstraram diferença entre os grupos no total da amostra. O GE demonstrou melhora em comparação ao GC na EF no 1º mês, e no VM nos 1° e 3º meses de seguimento. Quanto aos 12 pacientes com EM bilateral somente a EF demonstrou redução no GE no 1º mês de seguimento. Ao se avaliar os grupos separadamente, o GC apresentou agravamento da AV e SC durante todo seguimento. Houve também aumento da EF nos 1º e 6º meses e VM nos 1º , 3º e 6º meses de seguimento. O GE demonstrou estabilização da AV, SC, EF e VM. Correlacionado às funções visuais, AV com a SC, toda vez que houve piora da AV esta foi acompanhada pelo agravamento da SC em todos os momentos no GC e GE. Quando correlacionadas as AV e SC com as EF e VM, toda vez que a espessura macular aumentava, havia piora da função visual. Dos sete pacientes excluídos do estudo por apresentarem HV, cinco integravam o GC e dois o GE. Não houve aparecimento de catarata, endoftalmite e/ou aumento significativo da pressão ocular. CONCLUSÃO: Na RDP de alto risco, o uso adjuvante de injeções intravítreas de Bevacizumabe associadas à panfotocoagulação da retina pode estabilizar a AV, SC, EF e VM, diminuir a incidência de HV e reduzir a da espessura macular. Em relação à correlação entre as variáveis, quando houve piora da AV, esta foi acompanhada da piora da SC e o aumento da EF e VM causaram piora da AV e SC / INTRODUCTION: This study evaluated the treatment with intravitreal injections of Bevacizumab (IVB) associated with panretinal photocoagulation (PRP) in high-risk proliferative diabetic retinopathy (PDR) with or without diabetic macular edema (DME). METHODS: Prospective, open and masked, randomized clinical trial, composed of patients with type 2 Diabetes Mellitus (DM). The visual acuity (VA) was measured with the Early Treatment Diabetic Retinopathy Study charts and the contrast sensitivity (CS) through the chart of Vistech Consultants Incorporation 6500. Patients were submitted to a fluorescein angiography examination to observe retinal neovascularization and macular ischemia and to an optical coherence tomography (OCT) to obtain the foveal thickness (FT) and macular volume (MV). After the tests, one of the eyes from the same patient was randomized to realize only the PRP, the control group (CG), and the other for PRP associated to IVB injections, the study group (SG). Vitreous hemorrhage (VH) and presence of complications were also evaluated. RESULTS: Thirty-five of the forty-two patients included, completed the study. The mean age was 56±8 years, with a predominance of 21 (60%) males. Twenty-six (74%) patients had systemic hypertension with a mean duration of 9±10 years. The mean duration of DM was 18±9 years, of which 23 (66%) were insulin users and 21 (68.5%) were phakic. The VA and CS showed no difference between groups in the total sample. The SG showed improvement compared to the CG in FT for the 1st month, and in MV for the 1st and 3rd month of follow-up. As for the 12 patients with bilateral ME, only the FT showed a reduction in the SG for the 1st month of follow-up. When evaluating the groups separately, the CG showed worsening of VA and CS at all times. There was also an increase of FT for the 1st and 6th months and of MV for the 1st, 3rd and 6th month follow-up. The SG showed stabilization of VA, CS, FT and MV. When correlated to visual functions, VA and CS, a worsening of the VA was accompanied every time by a worsening of the CS in both the CG and SG. When VA and CS are correlated to FT and MV, there was worsening of visual function whenever macular thickness increased. Of the seven patients excluded from the study by presenting VH, 5 belonged to the CG and the 2 to the SG. There was no incidence of cataracts, endophthalmitis and/or significant increase in intraocular pressure. CONCLUSION: In high-risk PDR, intraocular injections of Bevacizumab as an adjuvant treatment to PRP, can stabilize VA, CS, FT and MV, reduce of the incidence of VH and decrease the macular thickness. Regarding the correlation between variables, when there was a worsening of VA, this was accompanied by a worsening of the CS, and an increase in FT and MV caused the worsening of the VA and CS

Objetivo: Comparar o efeito da terapia da fotocoagulação panretiniana (PFC) associada à injeção intravítrea de Ranibizumabe (RBZ) versus terapia isolada com PFC em pacientes com retinopatia diabética proliferativa (RDP) precoce, virgens de tratamento, com ou sem edema macular diabético (DME) durante 6 meses de acompanhamento. Projeto: Estudo prospectivo intervencionista, randomizado e controlado. Métodos: Sessenta olhos de 30 pacientes com RDP bilateral precoce foram randomizados para o grupo de estudo (GE) que foram tratados com PFC associado a duas injeções de RBZ intravítreo (0.5mg/0.05ml) ou para o grupo controle (GC) tratados apenas com PFC. Mudanças na acuidade visual (AV) corrigida, na sensibilidade ao contraste (SC) e na espessura foveal (EF) foram comparados no início, e nos 1, 3 e 6 meses após o tratamento. Resultados: No GE, a diferença na média da AV do baseline para o mês 6 teve um aumento significativo de + 3,4 letras (p = 0,006) e uma diminuição significativa na EF de - 47.6um (p < 0,001). No GC, a diferença na média da AV teve uma diminuição de - 3,4 letras (p = 0,04) e uma mudança na EF de -3.8 um (p = 0,96). Com relação ao teste de SC dentre os 28 olhos do GE, houve uma melhora no mês 6 em relação ao baseline nos ciclos: 1,5 (p < 0.001) e 3,0 ciclo (p=0.023). Dentre os 30 olhos do GC, não houve uma diferença estatística nos momentos estudados. Conclusão: A injeção intravítrea de RBZ associado com PFC pode ser um tratamento eficaz em olhos de pacientes com RDP precoce e EMD / Purpose: To compare the efficacy of therapy with panretinal photocoagulation (PRP) and intravitreal ranibizumab (RBZ) injection versus PRP alone in patients with treatment-naive bilateral non-high risk proliferative diabetic retinopathy (PDR) with and without diabetic macular edema (DME) with a 6-month follow-up. Design: Prospective, interventional, randomized controlled trial. Methods: Sixty eyes of 30 patients with bilateral non-high risk PDR were randomized either to the study group (SG) receiving PRP plus two intravitreal ranibizumab injections (0.5mg/0.05ml), the first one week before and the second four weeks after the PRP or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity (BCVA), contrast sensitivity (CS) and central macular thickness (CMT) were compared at baseline and 1, 3 and 6 months after treatment. Results: Changes from baseline to 6 months showed in the SG an increased in the BCVA by + 3.4 letters (p= 0.006) with a decrease in CMT by - 47.6um (p < 0.001). In the CG, a decrease by - 3.4 letters (p = 0.04) and an decrease by -3.8um (p= 0.96). Regarding the CS in the SG, there was an improvement compared to baseline for the sixth month in the 1.5 (p < 0.001) and 3.0 cycles (p = 0.023). The CG did not show significant results from baseline to month 6. Conclusion: Intravitreal RBZ associated with PRP can be an effective treatment in eyes with non-high risk PDR and DME

INTRODUÇÃO: O presente estudo avaliou o tratamento com injeções intravítreas de Bevacizumabe (IVB) associadas à panfotocoagulação (PFC) da retina na retinopatia diabética proliferativa (RDP) de alto risco com ou sem edema macular (EM). MÉTODOS: Ensaio clínico randomizado, prospectivo, aberto e mascarado composto por pacientes com Diabetes melitos (DM) tipo 2. A acuidade visual (AV) foi medida com a tabela Early Treatment Diabetic Retinopathy Study e a sensibilidade ao contraste (SC) pela da tabela Vistech Consultants Incorporation 6500. Os pacientes foram submetidos a exame de angiofluoresceinografia para observação de neovascularização retiniana e isquemia macular e à tomografia de coerência óptica (OCT), para se obter a espessura foveal (EF) e o volume macular (VM). Após os exames, um dos olhos do mesmo paciente foi randomizado para realizar somente PFC, grupo controle (GC), e o outro para PFC associado a injeções IVB, grupo de estudo (GE). A hemorragia vítrea (HV) e a presença de complicações também foram avaliadas. RESULTADOS: Dos 42 pacientes incluídos, 35 completaram o estudo. A média de idade foi de 56±8 anos, com predominância do gênero masculino 21 (60%). Vinte e seis (74%) pacientes eram portadores de Hipertensão Arterial Sistêmica com média de duração de 9±10 anos. A média de duração do DM foi de 18±9 anos sendo 23 (66%) usuários de insulina e 21 (68,5%), fácicos. A AV e a SC não demonstraram diferença entre os grupos no total da amostra. O GE demonstrou melhora em comparação ao GC na EF no 1º mês, e no VM nos 1° e 3º meses de seguimento. Quanto aos 12 pacientes com EM bilateral somente a EF demonstrou redução no GE no 1º mês de seguimento. Ao se avaliar os grupos separadamente, o GC apresentou agravamento da AV e SC durante todo seguimento. Houve também aumento da EF nos 1º e 6º meses e VM nos 1º , 3º e 6º meses de seguimento. O GE demonstrou estabilização da AV, SC, EF e VM. Correlacionado às funções visuais, AV com a SC, toda vez que houve piora da AV esta foi acompanhada pelo agravamento da SC em todos os momentos no GC e GE. Quando correlacionadas as AV e SC com as EF e VM, toda vez que a espessura macular aumentava, havia piora da função visual. Dos sete pacientes excluídos do estudo por apresentarem HV, cinco integravam o GC e dois o GE. Não houve aparecimento de catarata, endoftalmite e/ou aumento significativo da pressão ocular. CONCLUSÃO: Na RDP de alto risco, o uso adjuvante de injeções intravítreas de Bevacizumabe associadas à panfotocoagulação da retina pode estabilizar a AV, SC, EF e VM, diminuir a incidência de HV e reduzir a da espessura macular. Em relação à correlação entre as variáveis, quando houve piora da AV, esta foi acompanhada da piora da SC e o aumento da EF e VM causaram piora da AV e SC / INTRODUCTION: This study evaluated the treatment with intravitreal injections of Bevacizumab (IVB) associated with panretinal photocoagulation (PRP) in high-risk proliferative diabetic retinopathy (PDR) with or without diabetic macular edema (DME). METHODS: Prospective, open and masked, randomized clinical trial, composed of patients with type 2 Diabetes Mellitus (DM). The visual acuity (VA) was measured with the Early Treatment Diabetic Retinopathy Study charts and the contrast sensitivity (CS) through the chart of Vistech Consultants Incorporation 6500. Patients were submitted to a fluorescein angiography examination to observe retinal neovascularization and macular ischemia and to an optical coherence tomography (OCT) to obtain the foveal thickness (FT) and macular volume (MV). After the tests, one of the eyes from the same patient was randomized to realize only the PRP, the control group (CG), and the other for PRP associated to IVB injections, the study group (SG). Vitreous hemorrhage (VH) and presence of complications were also evaluated. RESULTS: Thirty-five of the forty-two patients included, completed the study. The mean age was 56±8 years, with a predominance of 21 (60%) males. Twenty-six (74%) patients had systemic hypertension with a mean duration of 9±10 years. The mean duration of DM was 18±9 years, of which 23 (66%) were insulin users and 21 (68.5%) were phakic. The VA and CS showed no difference between groups in the total sample. The SG showed improvement compared to the CG in FT for the 1st month, and in MV for the 1st and 3rd month of follow-up. As for the 12 patients with bilateral ME, only the FT showed a reduction in the SG for the 1st month of follow-up. When evaluating the groups separately, the CG showed worsening of VA and CS at all times. There was also an increase of FT for the 1st and 6th months and of MV for the 1st, 3rd and 6th month follow-up. The SG showed stabilization of VA, CS, FT and MV. When correlated to visual functions, VA and CS, a worsening of the VA was accompanied every time by a worsening of the CS in both the CG and SG. When VA and CS are correlated to FT and MV, there was worsening of visual function whenever macular thickness increased. Of the seven patients excluded from the study by presenting VH, 5 belonged to the CG and the 2 to the SG. There was no incidence of cataracts, endophthalmitis and/or significant increase in intraocular pressure. CONCLUSION: In high-risk PDR, intraocular injections of Bevacizumab as an adjuvant treatment to PRP, can stabilize VA, CS, FT and MV, reduce of the incidence of VH and decrease the macular thickness. Regarding the correlation between variables, when there was a worsening of VA, this was accompanied by a worsening of the CS, and an increase in FT and MV caused the worsening of the VA and CS

Les technologies d'imagerie intravasculaire c’est à dire l’échographie endo-coronaire (IVUS)et la tomographie par cohérence optique (IV-OCT) sont des outils précieux pour aider audiagnostic de la plaque d’athérosclérose et guider les gestes thérapeutiques.Le chapitre 1 présente les inconvénients de la coronarographie dans la pratique clinique.Dans plusieurs circonstances, l’IVUS et l’OCT ont clairement une valeur supplémentaire quandils sont utilisés comme un outil diagnostique en cas d'ambiguïtés angiographiques. Nousavons récemment rapporté la première observation utilisant l’OCT pour décrire une dissectioncoronaire d'une branche septale perforante responsable d’un infarctus du myocarde.Le chapitre 2 porte sur la reproductibilité de I’OCT entre différents instituts concernant denombreux paramètres qualitatifs et quantitatifs de la plaque d'athérome. Le but de notre étudeétait d'étudier en plus de la reproductibilité inter- et intra-observateur, la variabilité inter-institutsde I’OCT concernant les mesures quantitatives et qualitatives et de la comparer à celle del’IVUS. Dans ce travail, nous avons observé que, dans la mesure de la surface de la lumièreendocoronaire, des diamètres minimum et maximum de cette même lumière endocoronaire,de la surface endo-luminale du stent, des diamètres minimum et maximum endo-luminaux dustent, par des analystes provenant de 2 laboratoires différents, la reproductibilité inter-institutsde I’OCT était nettement supérieure à celle de l’IVUS. Le Chapitre 3 présente 2 nouvelles technologies robustes d'imagerie intravasculaire hybridesdéveloppées dans le laboratoire du Professeur Guillermo J. Tearney: l’OCT couplée à laspectroscopie dans le proche infra-rouge (OFDI-NIRS) et l’OCT couplée à l’autofluorescencedans le proche infra-rouge (OFDI-NIRAF). Les premières procédures d’OFDI-NIRS chezl’homme sont prévues dans un avenir proche. Les premières procédures chez l’homme ontété réalisées chez 12 patients porteurs d’un angor stable entre Juillet 2014 et Janvier 2015.Les résultats de cette étude pilote ont montré que le signal d’autofluorescence recueilli(NIRAF) a été focalement trés élevé dans des endroits de la plaque d’athérome où la plupartdes phénotypes morphologiques en OCT d’une plaque à haut risque de rupture étaientévidents. Les substrats biochimiques de ce signal d’autofluorescence (NIRAF) sont encore àélucider. / Intravascular imaging technologies i.e. IVUS and IV-OCT are valuable tools for interventionguidance and diagnostic plaque imaging.Chapter 1 introduces the drawbacks of coronary angiography in the clinical practice. In severalcircumstances, IVUS and IV-OCT have clearly an additional value when they are used as adiagnosis tool in case of angiographic ambiguities. We recently reported the first observationusing IV-OCT to describe a coronary dissection of a septal perforating branch causing AMI.Chapter 2 focuses on the inter-institute reliability of IV-OCT to determine qualitative andquantitative parameters of atherosclerotic plaque. The purpose of our study was to investigatefurther inter- and intra-observer reproducibility, the inter-institute variability for IV-OCT (OFDI)quantitative and qualitative measurements vs. IVUS measurements using publishedconsensus document definitions. In our work, we observed that in the measurement of lumenCSA, maximum and minimum lumen diameters, stent CSA, maximum and minimum stentdiameters by analysts from 2 different laboratories, inter-institute reproducibility of OFDI wasfound to be more consistent than IVUS.Chapter 3 present 2 new robust hybrid intravascular imaging technologies developed in Dr.Tearney’s laboratory i.e. OFDI-NIRS and OFDI-NIRAF, which may offer supplementary criteriafor plaque vulnerability. First-in-human OFDI-NIRS imaging procedures are anticipated in thenear future. First-in-human OFDI-NIRAF imaging procedures have been performed in a firstpioneering series of 12 stable patients between July 2014 and January 2015. Findings of thispilot study showed that NIRAF was focally elevated in plaque locations where most high-riskmorphologic phenotypes were evident. The biochemical substrates of the NIRAF signal stillhave to be elucidated.

Ce manuscrit de thèse de doctorat présente la conception et la réalisation d’un système d’imageriepour le diagnostic précoce des pathologies de la peau. Un diagnostic précoce permet de réduire lesactes chirurgicaux inutiles. Il est important de mettre en avant que seulement 20% des pathologiesfaisant office d’une opération chirurgicale, sont malignes. De plus, les pronostics de l’année 2015avançaient trois millions de nouveaux cas de cancer de la peau diagnostiqués aux ´ Etats-Unis. Basésur la tomographie par cohérence optique à balayage en longueur d’onde et une configuration pleinchamp et multi-canaux, le système d’imagerie médicale est capable d’imager en volume les couchesinternes de la peau et donc de fournir un diagnostic médical pour le professionnel de santé. Pourune fabrication en série du système portatif, les composants optiques sont micro-fabriqués sur dessubstrats et assemblés verticalement. Ces micro-composants optiques requièrent une caractérisationspécifique. Pour cela, deux systèmes ont ainsi été développés pour estimer leurs performancesoptiques. Ce travail a été réalisé dans le cadre du projet Européen VIAMOS (Vertically IntegratedArray-type Mirau-based OCT System). / The manuscript concerns the optical design and the development of a non-invasive new imagingsystem for the early diagnosis of skin pathologies. Indeed, an early diagnosis can make the differencebetween malignant and benign skin lesion in order to minimize unnecessary surgical procedure.Furthermore, prognosis for the year 2015 was that more than three millions new skin cancer caseswill be diagnosed in the United States. Based on the swept source optical coherence tomographytechnique in full-field and multiple channels configuration, the imaging system is able to perform avolumetric image of the subsurface of the skin, and thus can help in taking a better medical decision.Furthermore, for a batch-fabrication of the hand-held device, micro-optical components were made atwafer-level and vertically assembled using multi-wafer bonding. This miniaturized system requiresspecific characterization. Thus, two systems were also developed for imaging quality evaluation ofmicro-optical elements. This work has been supported by the VIAMOS (Vertically Integrated ArraytypeMirau-based OCT System) European project.

Le glaucome est la première cause de cécité irréversible dans le monde. Bien que sa pathogenèse demeure encore nébuleuse, les propriétés biomécaniques de l’oeil sembleraient jouer un rôle important dans le développement et la progression de cette maladie. Il est stipulé que la rigidité oculaire (RO) est altérée au travers les divers stades de la maladie et qu’elle serait le facteur le plus influent sur la réponse du nerf optique aux variations de la pression intraoculaire (PIO) au sein du glaucome. Pour permettre l’investigation du rôle de la RO dans le glaucome primaire à angle ouvert (GPAO), la capacité de quantifier la RO in vivo par l’entremise d’une méthode fiable et non-invasive est essentielle. Une telle méthode n’est disponible que depuis 2015. Basée sur l'équation de Friedenwald, cette approche combine l'imagerie par tomographie par cohérence optique (TCO) et la segmentation choroïdienne automatisée afin de mesurer le changement de volume choroïdien pulsatile (ΔV), ainsi que la tonométrie dynamique de contour Pascal pour mesurer le changement de pression pulsatile correspondant. L’objectif de cette thèse est d’évaluer la validité de cette méthode, et d’en faire usage afin d’investiguer le rôle de la RO dans les maladies oculaires, particulièrement le GPAO. Plus spécifiquement, cette thèse vise à : 1) améliorer la méthode proposée et évaluer sa validité ainsi que sa répétabilité, 2) investiguer l’association entre la RO et le dommage neuro-rétinien chez les patients glaucomateux, et ceux atteints d’un syndrome de vasospasticité, 3) évaluer l’association entre la RO et les paramètres biomécaniques de la cornée, 4) évaluer l’association entre la RO et les pics de PIO survenant suite aux thérapies par injections intravitréennes (IIV), afin de les prédire et de les prévenir chez les patients à haut risque, et 5) confirmer que la RO est réduite dans les yeux myopes. D’abord, nous avons amélioré le modèle mathématique de l’oeil utilisé pour dériver ΔV en le rendant plus précis anatomiquement et en tenant compte de la choroïde périphérique. Nous avons démontré la validité et la bonne répétabilité de cette méthodologie. Puis, nous avons effectué la mesure des coefficients de RO sur un large éventail de sujets sains et glaucomateux en utilisant notre méthode non-invasive, et avons démontré, pour la première fois, qu'une RO basse est corrélée aux dommages glaucomateux. Les corrélations observées étaient comparables à celles obtenues avec des facteurs de risque reconnus tels que la PIO maximale. Une forte corrélation entre la RO et les dommages neuro-rétiniens a été observée chez les patients vasospastiques, mais pas chez ceux atteints d'une maladie vasculaire ischémique. Cela pourrait potentiellement indiquer une plus grande susceptibilité au glaucome due à la biomécanique oculaire chez les patients vasospastiques. Bien que les paramètres biomécaniques cornéens aient été largement adoptés dans la pratique clinique en tant que substitut pour la RO, propriété biomécanique globale de l'oeil, nous avons démontré une association limitée entre la RO et ces paramètres, offrant une nouvelle perspective sur la relation entre les propriétés biomécaniques cornéennes et globales de l’oeil. Seule une faible corrélation entre le facteur de résistance cornéenne et la RO demeure après ajustement pour les facteurs de confusion dans le groupe des patients glaucomateux. Ensuite, nous avons présenté un modèle pour prédire l'amplitude des pics de PIO après IIV à partir de la mesure non-invasive de la RO. Ceci est particulièrement utile pour les patients à haut risque atteints de maladies rétiniennes exsudatives et de glaucome qui nécessiteraient des IIV thérapeutiques, et pourrait permettre aux cliniciens d'ajuster ou de personnaliser le traitement pour éviter toute perte de vision additionnelle. Enfin, nous avons étudié les différences de RO entre les yeux myopes et les non-myopes en utilisant cette technique, et avons démontré une RO inférieure dans la myopie axiale, facteur de risque du GPAO. Dans l'ensemble, ces résultats contribuent à l’avancement des connaissances sur la physiopathologie du GPAO. Le développement de notre méthode permettra non seulement de mieux explorer le rôle de la RO dans les maladies oculaires, mais contribuera également à élucider les mécanismes et développer de nouveaux traitements ciblant la RO pour contrer la déficience visuelle liée à ces maladies. / Glaucoma is the leading cause of irreversible blindness worldwide. While its pathogenesis is yet to be fully understood, the biomechanical properties of the eye are thought to be involved in the development and progression of this disease. Ocular rigidity (OR) is thought to be altered through disease processes and has been suggested to be the most influential factor on the optic nerve head’s response to variations in intraocular pressure (IOP) in glaucoma. To further investigate the role of OR in open-angle glaucoma (OAG) and other ocular diseases such as myopia, the ability to quantify OR in living human eyes using a reliable and non-invasive method is essential. Such a method has only become available in 2015. Based on the Friedenwald equation, the method uses time-lapse optical coherence tomography (OCT) imaging and automated choroidal segmentation to measure the pulsatile choroidal volume change (ΔV), and Pascal dynamic contour tonometry to measure the corresponding pulsatile pressure change. The purpose of this thesis work was to assess the validity of the methodology, then use it to investigate the role of OR in ocular diseases, particularly in OAG. More specifically, the objectives were: 1) To improve the extrapolation of ΔV and evaluate the method’s validity and repeatability, 2) To investigate the association between OR and neuro-retinal damage in glaucomatous patients, as well as those with concomitant vasospasticity, 3) To evaluate the association between OR and corneal biomechanical parameters, 4) To assess the association between OR and IOP spikes following therapeutic intravitreal injections (IVIs), to predict and prevent them in high-risk patients, and 5) To confirm that OR is lower in myopia. First, we improved the mathematical model of the eye used to derive ΔV by rendering it more anatomically accurate and accounting for the peripheral choroid. We also confirmed the validity and good repeatability of the method. We carried out the measurement of OR coefficients on a wide range of healthy and glaucomatous subjects using this non-invasive method, and were able to show, for the first time, that lower OR is correlated with more glaucomatous damage. The correlations observed were comparable to those obtained with recognized risk factors such as maximum IOP. A strong correlation between OR and neuro-retinal damage was found in patients with concurrent vasospastic syndrome, but not in those with ischemic vascular disease. This could perhaps indicate a greater susceptibility to glaucoma due to ocular biomechanics in vasospastic patients. While corneal biomechanical parameters have been widely adopted in clinical practice as surrogate measurements for the eye’s overall biomechanical properties represented by OR, we have shown a limited association between these parameters, bringing new insight unto the relationship between corneal and global biomechanical properties. Only a weak correlation between the corneal resistance factor and OR remained in glaucomatous eyes after adjusting for confounding factors. In addition, we presented a model to predict the magnitude of IOP spikes following IVIs from the non-invasive measurement of OR. This is particularly useful for high-risk patients with exudative retinal diseases and glaucoma that require therapeutic IVIs, and could provide the clinician an opportunity to adjust or customize treatment to prevent further vision loss. Finally, we investigated OR differences between non-myopic and myopic eyes using this technique, and demonstrated lower OR in axial myopia, a risk factor for OAG. Overall, these findings provide new insights unto the pathophysiology of glaucomatous optic neuropathy. The development of our method will permit further investigation of the role of OR in ocular diseases, contributing to elucidate mechanisms and provide novel management options to counter vision impairment caused by these diseases.

In this work is describe anatomy and physiology of the cornea. The following are the primary non-inflamatory degeneration of the cornea. Then describe the physical principles diagnostic devices for cornea – keratometer, pachymeter, Michelson interferometr and optical coherence tomography (OCT). At the end of the theoretical introduction is describes the principle of laser correction surgery – LASIK. The practical part is divided into two main objectives. The first task is propose an algorithm for automatic detection of corneal surface and then calculation of corneal thickness and size of the chamber angle in Matlab. The aim of the second task is image flap analysis for boundary detection.

La sclérose en plaques est une maladie dégénérative qui peut affecter la vision ainsi que différentes structures du système visuel afférent. La partie de l'oeil plus souvent affectée par la sclérose en plaques est le nerf optique, sous forme de névrite optique. Une technologie, nommée TCO (tomographie par cohérence optique), permet de prendre une image du nerf optique et de ses fibres nerveuses qui s'étendent sur la rétine. Dans cette thèse, la TCO a permis d’obtenir une épaisseur des fibres nerveuses autour du nerf optique, ainsi qu’une épaisseur totale de la macula et de la couche de cellules ganglionnaires chez les patients atteints de sclérose en plaques, avec et sans histoire de nérite optique, et chez un groupe de patients contrôle. Les résultats démontrent que seule l’épaisseur de la couche de cellules ganglionnaires permet de différentier les patients avec sclérose en plaques sans histoire de névrite optique des patients contrôle. Une deuxième étude a évalué la qualité visuelle en mesurant la sensibilité aux contrastes ainsi que la qualité de vie reliée à la vision avec un questionnaire de qualité de vie. Les résultats démontrent qu’une nouvelle charte de sensibilité aux contrastes, plus facile à administrer en clinique, permet aussi de différentier les patients sans névrite optique du groupe contrôle. De plus, la qualité de vie des patients ayant eu un épisode de névrite optique semble significativement affectée, même si le pronostic est considéré très favorable et que l’acuité visuelle est « bonne » suite à une névrite optique. En conclusion, l’utilisation de l’OCT en plus de mesures sensibles de fonction visuelle, telle la sensibilité aux contrastes, et de qualité de vié peuvent contribuer à mieux détecter des dysfonctions oculo-visuelles subtiles, mais importantes chez les patients atteints de sclérose en plaques. / Multiple sclerosis (MS) is the most common neurological condition causing disability in working-age adults. The hallmark of MS related disability is axonal loss. Through new technologies, such as optical coherence tomography (OCT), the retinal nerve fibre layer (RNFL), composed of ganglion cell axons, can be visualized and studied non-invasively in cross-section. Furthermore, recent OCT advances allow precise retinal layer segmentation and macular imaging of the ganglion cell layer. In this thesis, these different OCT parameters were measured to see which layers would be most affected in MS patients without previous optic neuritis. Results show that macular ganglion cell layer thickness is the only OCT parameter that can differentiate this sub-group of patients from healthy controls. Visual function was then assessed using a newly available, easy to use contrast sensitivity chart that can be self-administered by patients. Results show that this chart is also capable of differentiating MS patients without optic neuritis from controls, but usually gives better contrast sensitivity scores than the Mars chart. Lastly, vision-specific quality of life was assessed and proved to be reduced in MS patients with prior optic neuritis, despite supposed favorable recovery and good visual acuity in patients with this diagnosis. In sum, the use of OCT imaging, as well as sensitive visual function and quality of life measures, could help detect subtle, yet important structural or functional visual changes in patients with MS. This could ultimately help better screen, manage and counsel this subset of patients.

Indiana University-Purdue University Indianapolis (IUPUI) / Adaptive optics-optical coherence tomography (AO-OCT) is a non-invasive method of imaging the human retina in vivo. It can be used to visualize microscopic structures, making it incredibly useful for the early detection and diagnosis of retinal disease. The research group at Indiana University has a novel multi-camera AO-OCT system capable of 1 MHz acquisition rates. Until this point, a method has not existed to process data from such a novel system quickly and accurately enough on a CPU, a GPU, or one that can scale to multiple GPUs automatically in an efficient manner. This is a barrier to using a MHz AO-OCT system in a clinical environment. A novel approach to processing AO-OCT data from the unique multi-camera optics system is tested on multiple graphics processing units (GPUs) in parallel with one, two, and four camera combinations. The design and results demonstrate a scalable, reusable, extensible method of computing AO-OCT output. This approach can either achieve real time results with an AO-OCT system capable of 1 MHz acquisition rates or be scaled to a higher accuracy mode with a fast Fourier transform of 16,384 complex values.

Roll-to-roll manufacturing of micro components based on advanced printing, structuring and lamination of ceramic tapes is rapidly progressing. This large-scale and cost-effective manufacturing process of ceramic micro devices is however prone to hide defects within the visually opaque tape stacks. To achieve a sustainable manufacturing with zero defects in the future, there is an urgent need for reliable inspection systems. The systems to be developed have to perform high-resolution in-process quality control at high speed. Optical coherence tomography (OCT) is a promising technology for detailed in-depth inspection and metrology. Combined with infrared screening of larger areas it can solve the inspection demands in the roll-to-roll ceramic tape processes. In this thesis state-of-art commercial and laboratory OCT systems, operating at the central wavelength of 1.3 µm and 1.7 µm respectively, are evaluated for detecting microchannels, metal prints, defects and delaminations embedded in alumina and zirconia ceramic layers at hundreds of micrometers beneath surfaces. The effect of surface roughness induced scattering and scattering by pores on the probing radiation, is analyzed by experimentally captured and theoretically simulated OCT images of the ceramic samples, while varying surface roughnesses and operating wavelengths. By extending the Monte Carlo simulations of the OCT response to the mid-infrared the optimal operating wavelength is found to be 4 µm for alumina and 2 µm for zirconia. At these wavelengths we predict a sufficient probing depth of about 1 mm and we demonstrate and discuss the effect of rough surfaces on the detectability of embedded boundaries. For high-precision measurement a new and automated 3D image processing algorithm for analysis of volumetric OCT data is developed. We show its capability by measuring the geometric dimensions of embedded structures in ceramic layers, extracting features with irregular shapes and detecting geometric deformations. The method demonstrates its suitability for industrial applications by rapid inspection of manufactured samples with high accuracy and robustness. The new inspection methods we demonstrate are finally analyzed in the context of measurement uncertainty, both in the axial and lateral cases, and reveal that scattering in the sample indeed affects the lateral measurement uncertainty. Two types of image artefacts are found to be present in OCT images due to multiple reflections between neighboring boundaries and inhomogeneity of refractive index. A wavefront aberration is found in the OCT system with a scanning scheme of two galvo mirrors, and it can be corrected using our image processing algorithm. / <p>QC 20140428</p> / Multilayer (FP7-NMP4-2007-214122)